Simmunext Biotherapeutics’ leadership team and its partners bring top notch science and industrial expertise in tumor immunology, biotech and pharma to the table.
CEO & co-founder
Henri Theunissen holds a PhD in molecular biology (NKI, Amsterdam) and has a long-standing background in biotechnology and oncology. He gained extensive science business experience in biotech and pharma (Organon, Schering-Plough, later Merck). As CEO of Knowledge Transfer Funds BV and Chief Innovation Officer (Brightlands) he has founded and grown over 30 startup companies.
CSO & co-founder
Carl Figdor is a professor of Immunology, Spinoza laureate, KNAW member and multiple ERC laureate. He has an impressive scientific track record in immuno-oncology, developed several cancer vaccines (dendritic cells, nanoparticles) and translated these into the clinic. More recently, he focused on chemical immunology approaches to develop synthetic dendritic cells, resulting in our immunofilaments technology platform.